Psychedelics
Numinus to Sell C$10M Worth of New Shares Through Equity Program
The exact number of shares to be sold will be determined by Numinus’ financier.
The post Numinus to Sell C$10M Worth of New Shares Through Equity Program…
Vancouver-based psychedelics company Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) on Tuesday announced that it will attempt to raise C$10 million by selling more common shares through an at-the-market equity program.
The exact number of shares to be sold, however, will be determined by Numinus’ financier, Stifel Nicolaus Canada Inc., which holds an “equity distribution agreement” that governs the equity program shares, according to a press release.
The funding mechanism “provides (Numinus) with enhanced flexibility should future additional financing be required, and it may be activated if and as deemed appropriate,” the company said in the release.
Revenue from shares sold will be used “for general corporate purposes (including funding ongoing operations and/or working capital requirements), to repay indebtedness outstanding from time to time, discretionary capital programs and potential future acquisitions,” according to the release.
Based on its recent financials, Numinus likely needs a cash infusion in order to confidently continue operations. In the quarter that ended May 31, Numinus burned through $9.2 million in operating expenditures, posted a net loss of $7.2 million, and was left with $13 million in cash.
Still, the company may be poised for a major breakthrough, if the U.S. Food and Drug Administration gives the green light to its MDMA-assisted therapy next year, as the company hopes.
The post Numinus to Sell C$10M Worth of New Shares Through Equity Program appeared first on Green Market Report.
Psychedelic Search Trends in 2023
Take a look at this 2023 search volume chart. Do you think you can guess what’s happening? I was pretty shocked when I noticed this spike for December…
Here Are the Champions! Our Top Performing Stories in 2023
It has been quite a year – not just for the psychedelic industry, but also for humanity as a whole. Volatile might not be the most elegant word for it,…
Psilocybin shows promise for treating eating disorders, but more controlled research is needed
Recent psychedelic research shows promising results for mental illnesses and eating disorders, with surveys and reports indicating psilocybin-assisted…